Key Highlights

  • DexCom is the commercial heavyweight here, with second-quarter worldwide Revenue of $1.31 billion, up 13%.
  • Prothena reported first-quarter Net Income of $32.7 million and holds cash of $330.3 million, giving it a fortress-like balance sheet.
  • Grace Therapeutics is reworking its regulatory path after the FDA issued a Complete Response Letter for GTx-104 on April 23, 2026.
  • Longeveron and Phio Pharmaceuticals are both event-driven micro-caps, with Longeveron's pivotal HLHS trial and Phio's limited cash runway as key watch items.

Grouping five tickers under one headline is a convenience, not a thesis. Longeveron (NASDAQ:LGVN), DexCom (NASDAQ:DXCM), Grace Therapeutics (NASDAQ:GRCE), Prothena (NASDAQ:PRTA) and Phio Pharmaceuticals (NASDAQ:PHIO) share a Nasdaq listing and a healthcare label, and little else. One is a profitable, multi-billion-dollar device maker; three are clinical-stage developers whose fortunes hinge on single regulatory or data events; one sits somewhere between, funded by big-pharma partners.

What makes September 2026 a useful moment to look at them together is timing. Several face near-term catalysts, and the sector backdrop, still shaped by the cost of capital, rewards cash-rich names and punishes those approaching the end of their runway. Read each on its own facts below.

The Sector Backdrop Heading Into Autumn 2026

Two forces dominate small- and mid-cap biotech sentiment this year. The first is funding. After a prolonged stretch of expensive capital, developers without product revenue live and die by cash runway, and dilution remains the default financing tool for micro-caps. The second is regulatory throughput: an FDA decision, a Complete Response Letter, or a Type C meeting can reprice a small company overnight, while it barely moves a diversified device maker.

Against that, the five names split cleanly. DexCom is the commercial anchor, exposed to reimbursement, competition and Manufacturing execution rather than binary trial risk. Longeveron, Grace and Phio are event-driven: each has a defined near-term milestone that could dominate its 2026. Prothena is the hybrid, carrying a large cash balance and a pipeline largely de-risked onto the balance sheets of Roche, Novo Nordisk and Bristol Myers Squibb.

The themes below, regenerative medicine, continuous glucose monitoring, rare-disease specialty pharma, neurodegeneration and RNAi, map onto those profiles. Where a number appears, it traces to a company filing, press release or an Earnings account cited at the end.

Longeveron (NASDAQ:LGVN): A Regenerative-Medicine Micro-Cap With a September Catalyst

Longeveron is the archetypal event-driven micro-cap. Its lead cell therapy, laromestrocel (Lomecel-B), is being studied in hypoplastic left heart syndrome (HLHS), a rare and severe congenital heart defect, and in Alzheimer's disease. The company said its pivotal Phase 2b ELPIS II trial in HLHS was on track for top-line results in September 2026, with enrollment complete and an independent Data Monitoring Committee having completed a final review in May 2026 without flagging safety concerns. Ahead of that readout, Longeveron announced in January 2026 that the FDA had granted a Type C meeting, held around late March, to align on the efficacy endpoints and statistical analysis plan that would support a potential Biologics License Application. In the HLHS program, laromestrocel carries Orphan Drug, Fast Track and Rare Pediatric Disease designations; the Alzheimer's program holds RMAT and Fast Track status. The Type C meeting matters because agreement on the endpoint is what separates a "positive" readout that supports a filing from one that does not. Longeveron reported $10.1 million of cash at June 30, 2026, a Q2 net loss of $6.1 million, and a runway it described as reaching into the fourth quarter of 2026. That timeline implies financing pressure around the very period the data lands, a combination that can amplify moves in either direction.

DexCom (NASDAQ:DXCM): The Continuous-Glucose Anchor of the Group

DexCom is the commercial heavyweight and the clearest health-technology name here, a leader in continuous glucose monitoring (CGM). For the second quarter of 2026, DexCom reported worldwide revenue of $1.31 billion, up 13% year over year, with US revenue of $933 million (up 11%) and international revenue of $375 million (up 19% as reported). Operating Income was $328.3 million, or 25.1% of revenue. The company raised full-year 2026 revenue guidance to a range of $5.18 billion to $5.25 billion, with gross Margin around 64% and Operating Margin of 23.5% to 24%. Management said its G7 15-day sensor was on track to convert nearly half of US customers by year-end and cited a quarterly gross margin of 64.1%, up about 400 basis points year over year. DexCom's story is execution rather than binary risk, hardware transitions, international tender timing, and expanding beyond insulin-using diabetics through the over-the-counter Stelo product aimed at type 2 patients not on insulin. Management flagged an expected foreign-exchange headwind in the second half, and CGM remains a competitive category. Guidance is company forecast, not a promise.

Grace Therapeutics (NASDAQ:GRCE): A Rare-Disease Name Reworking Its Path to Approval

Grace Therapeutics is a specialty rare-disease developer whose lead asset, GTx-104, is an intravenous formulation of nimodipine for patients with aneurysmal subarachnoid hemorrhage (aSAH). The FDA issued a Complete Response Letter for the GTx-104 New Drug Application on April 23, 2026. In materials describing subsequent Type A meeting minutes (announced July 28, 2026), Grace said the agency did not identify clinical safety or efficacy deficiencies and did not request additional clinical data; the letter instead centered on chemistry-and-manufacturing matters, cited as cGMP compliance at a contract manufacturing facility, additional leachables data, and excipient toxicology risk assessments. The company outlined a dual-source manufacturing strategy for resubmission and disclosed a $10 million private Placement to fund it. Its STRIVE-ON trial had compared GTx-104 against oral nimodipine and met its primary endpoint. A manufacturing-only CRL is generally viewed as more addressable than one demanding fresh clinical trials, because the clinical case is not in dispute. "more addressable" is not "certain." No new PDUFA date was specified in the materials reviewed, and a technology transfer to a second manufacturer takes time. For a small company, each quarter of delay carries financing implications.

Prothena (NASDAQ:PRTA): Neurodegeneration and Protein Misfolding, Largely Partnered

Prothena works in protein-misfolding diseases, the biology behind Parkinson's, Alzheimer's and transthyretin (ATTR) amyloidosis, and has structured much of its pipeline around large partners. For the first quarter of 2026, Prothena reported net income of $32.7 million and cash of $330.3 million at March 31, 2026, with revenue of $51.1 million driven largely by a $50 million Novo Nordisk milestone. The company guided to 2026 net cash use of roughly $18 million to $23 million. Its partnered programs include prasinezumab in Parkinson's with Roche (Phase 3 PARAISO), coramitug/PRX004 in ATTR cardiomyopathy with Novo Nordisk (Phase 3 CLEOPATTRA, with Fast Track designation), and BMS-986446/PRX005 in Alzheimer's with Bristol Myers Squibb (Phase 2 TargetTau-1). A separate BMS program, PRX019, carried a potential milestone tied to an advancement decision expected by end-2026. Prothena's appeal is optionality funded by others; its risk is that it is a step removed from the programs most likely to move its stock. This partnership-heavy posture followed an earlier setback in its wholly owned AL amyloidosis candidate. Milestone timing, not Prothena's own trials, is the near-term swing factor.

Phio Pharmaceuticals (NASDAQ:PHIO): An RNAi Micro-Cap at an FDA Crossroads

Phio Pharmaceuticals is a clinical-stage RNAi developer built around its INTASYL siRNA platform, designed to silence genes such as PD-1 directly inside tumors. Phio reported $17.0 million of cash at March 31, 2026 and a first-quarter net loss of $4.0 million, describing a runway extending into the first half of 2027 and citing an ATM Facility of about $6.36 million entered in April 2026. Its lead candidate, PH-762, completed the clinical phase of a Phase 1b intratumoral study enrolling 22 patients, most with cutaneous squamous cell carcinoma, with final data being analyzed. The company said it targeted a mid-2026 FDA submission to seek guidance on the design of its next clinical study, and it flagged a data presentation at the American Academy of Dermatology's 2026 meeting. PH-762's local-delivery approach is scientifically distinctive, and completing the clinical phase is a genuine step. A Phase 1b in roughly two dozen patients is a signal-finding exercise, not proof of efficacy, and micro-cap RNAi names remain among the most dilution-prone in the sector. The FDA interaction and the next-study design are what to watch.

What Investors Should Watch

For Longeveron, the September ELPIS II readout, and how it maps onto the endpoints discussed at the Type C meeting, is the defining event, with cash runway as the backdrop. For DexCom, watch the G7 15-day conversion, Stelo traction, international tender timing and whether raised guidance holds. For Grace, the practical question is when a manufacturing-focused resubmission can be filed and accepted, and how it is funded. For Prothena, milestone flow from Roche, Novo Nordisk and Bristol Myers Squibb, plus the PRX019 decision, will drive sentiment more than its own studies. For Phio, the FDA's guidance on the next PH-762 trial, and the terms of any financing, matter most.

One Bellwether, Four Concentrated Bets

Reading them together, these five names illustrate how wide the "healthcare on Nasdaq" tent really is. DexCom offers scale and cash generation with execution risk; Prothena offers a fortress Balance Sheet and partnered optionality; Longeveron, Grace and Phio offer concentrated, event-driven exposure where a single readout or filing can dominate the year. The facts above are dated and sourced; the forecasts are explicitly hedged; and the risks, from dilution to regulatory delay, are as much a part of each story as the catalysts.